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Introduction
About 10-20% of familial Mediterranean fever (FMF)
patients do not achieve complete remission, due to colchi-
cine resistance or sensitivity. Disease control in these
patients is still an unmet challenge. Case reports and a
small case control study, suggest a role for interleukin 1
beta blockage, particularly anakinra, in the management of
this limitation of colchicines.
Objectives
To embark on a study, evaluating the efficacy and safety
of anakinra in the treatment of colchicine refractory
FMF.
Methods
We plan to include patients, agreeing with clinical and
genetic diagnosis of FMF, who suffer from FMF attacks, at
least once per month, in one of the sites commonly
involved by FMF (Chest, abdomen, lower extremity large
joints, and skin), despite treatment with colchicine 2 mg/
day or less (in case of colchicine intolerance). Involvement
with other diseases relevant (vasculitis, spondyloarthropa-
thy, Behcet’s disease, etc.), or irrelevant (rheumatoid
arthritis, SLE, etc.), to FMF, or possible non compliance,
will serve as exclusion criteria. The study is planned to
continue for 4 months per patient, in which patients will
receive anakinra (s.c. 100 mg/day, 25 patients), or control
drug (anakinra vehicle, same volume, same package,
25 patients). Randomization will be sequential for a prede-
termined order of the interventional drug (anakinra or
vehicle), for which the study team will be blinded. Analysis
of the results will be performed by an external company.
Anakinra effect will be compared to placebo effect by
computing the reduction of number of attacks per each
patient. Secondary outcome include reduction of severity
of attacks.
Results
No results are yet available. The study is an investigator
initiative project, with sponsorship of the manufacturing
drug company. Measurements were taken to avoid any
bias in the performance of the study or interpretation of
the results. It is expected that the whole study will con-
tinue 2 years.
Conclusion
A favorable anakinra effect in the prevention of FMF
attacks in colchicine failure, supported by ample case
reports is expected to be confirmed by the present con-
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